93467-56-2

Basic information

• Product Name: (3,4-DICHLOROPHENYL)ACETALDEHYDE
• Synonyms: (3,4-DICHLOROPHENYL)ACETALDEHYDE
• CAS NO: 93467-56-2
• Molecular Formula: C₈H₆Cl₂O
• Molecular Weight: 189.04
• Product Categories: Aromatic Aldehydes & Derivatives (substituted)
• Mol File: 93467-56-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: (3,4-DICHLOROPHENYL)ACETALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: (3,4-DICHLOROPHENYL)ACETALDEHYDE(93467-56-2)
• EPA Substance Registry System: (3,4-DICHLOROPHENYL)ACETALDEHYDE(93467-56-2)

Safety Data

• Hazardous Substances Data: 93467-56-2(Hazardous Substances Data)

Usage

Description

(3,4-DICHLOROPHENYL)ACETALDEHYDE is an organic compound characterized by the presence of a chlorine atom at both the 3rd and 4th positions on a phenyl ring, with an acetaldehyde group attached to it. This chemical structure endows it with specific reactivity and properties that make it suitable for various applications in the chemical and pharmaceutical industries.

Uses

Used in Pharmaceutical Industry:
(3,4-DICHLOROPHENYL)ACETALDEHYDE is used as a reagent for the preparation of cyanopyridone-based anti-tuberculosis agents. Its unique structure allows it to participate in chemical reactions that lead to the synthesis of these important drugs, which are crucial in the treatment of tuberculosis, a significant global health concern.

Upstream product

• 5807-30-7 3,4-dichlorophenyl acetic acid 
• 35364-79-5 2-(3,4-dichlorophenyl)ethanol 

Downstream Products

• 1233691-99-0 (2S,3S)-2-(3,4-dichlorophenyl)3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-4-nitrobutyraldehyde 
• 868697-78-3 3,4-dichlorophenylacetamide 
• 107919-69-7 (E)-1,2-dichloro-4-[2-(4-methylbenzene)sulfonylvinyl]benzene 

Relevant articles and documents

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors

We are concerned with the development of novel anti-infectives with dual antibacterial and antiretroviral activities for MRSA/HIV-1 co-infection. To achieve this goal, we exploited for the first time the mechanistic function similarity between the bacterial RNA polymerase (RNAP) "switch region" and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site. Starting from our previously discovered RNAP inhibitors, we managed to develop potent RT inhibitors effective against several resistant HIV-1 strains with maintained or enhanced RNAP inhibitory properties following a structure-based design approach. A quantitative structure-activity relationship (QSAR) analysis revealed distinct molecular features necessary for RT inhibition. Furthermore, mode of action (MoA) studies revealed that these compounds inhibit RT noncompetitively, through a new mechanism via closing of the RT clamp. In addition, the novel RNAP/RT inhibitors are characterized by a potent antibacterial activity against S. aureus and in cellulo antiretroviral activity against NNRTI-resistant strains. In HeLa and HEK 293 cells, the compounds showed only marginal cytotoxicity.

Expanding the scaffold for bacterial RNA polymerase inhibitors: Design, synthesis and structure-activity relationships of ureido-heterocyclic-carboxylic acids

The emergence of bacterial resistance requires the development of new antibiotics with an alternative mode of action. Based on class I, developed in our previous study, a new series of RNA polymerase (RNAP) inhibitors targeting the switch region was desig